Second Opinion | Contact Us

Autoimmune Liver

The immune system’s job is to protect against infections and foreign threats. In autoimmune liver diseases, it mistakes the liver’s own cells for the enemy – and the resulting inflammation damages the liver over time. These conditions are less common than viral hepatitis, but they’re often underdiagnosed because symptoms can be vague and overlap with many other illnesses.

The Three Main Types of Autoimmune Liver Disease

Autoimmune Hepatitis (AIH) The immune system attacks hepatocytes, causing chronic inflammation. Without treatment, it can progress to cirrhosis. It responds well to immunosuppressive therapy when caught early.

Primary Biliary Cholangitis (PBC) The immune system targets the small bile ducts inside the liver. More common in middle-aged women. Damaged ducts lead to bile buildup, which damages liver cells over years.

Primary Sclerosing Cholangitis (PSC) Inflammation and scarring of both intra- and extra-hepatic bile ducts. More common in men; strongly associated with inflammatory bowel disease. Carries a higher risk of bile duct cancer (cholangiocarcinoma).

Symptoms

  • Fatigue often disproportionate to the degree of liver damage
  • Itching (pruritus) – particularly prominent in PBC; caused by bile salt deposition in the skin
  • Jaundice – yellowing of skin and eyes
  • Joint pain – more common in AIH
  • Dry eyes and dry mouth (Sicca syndrome) – seen in some PBC patients

Diagnosis

  • LFTs elevated ALT/AST in AIH; elevated ALP and GGT in PBC/PSC
  • Autoantibodies – ANA, SMA (AIH); AMA – Anti-Mitochondrial Antibody (PBC)
  • IgG levels – elevated in AIH; IgM elevated in PBC
  • MRCP – key investigation for PSC, showing the ‘beaded’ bile duct pattern
  • Liver biopsy – often needed to confirm diagnosis and assess fibrosis

Autoimmune Liver Disease Treatment

Autoimmune Hepatitis Prednisolone (often combined with Azathioprine) – most patients achieve remission. Treatment is usually lifelong. Mycophenolate mofetil is an alternative for those who don’t tolerate Azathioprine.

Primary Biliary Cholangitis Ursodeoxycholic acid (UDCA) daily improves liver enzymes and slows progression in most patients. Obeticholic acid is second-line for non-responders.

Primary Sclerosing Cholangitis No proven disease-modifying drug yet. Dominant strictures can be treated endoscopically. Liver transplantation is the only treatment for end-stage PSC. Regular surveillance for bile duct cancer (annual MRCP and CA 19-9) is important.

Yes. Autoimmune hepatitis can affect people of any age, including children and teenagers. It's actually one of the more common causes of chronic liver disease in young women. PBC tends to present in middle-aged women, while PSC more often affects younger men. None of these conditions are restricted to older adults.

Yes - most patients achieve biochemical remission with prednisolone and azathioprine. However, remission requires continued medication for most people. Attempting to stop treatment leads to relapse in the majority of patients (60–80%). A small number who have been in prolonged, deep remission may be carefully withdrawn from treatment under specialist guidance.

No, though both involve bile ducts. PBC affects the small bile ducts inside the liver and is more common in women. PSC affects both the small ducts inside the liver and the larger ducts outside it, is more common in men, and is closely associated with inflammatory bowel disease. Their treatments and surveillance protocols also differ significantly.

The exact trigger isn't fully established. A genetic predisposition combined with an environmental trigger - possibly a viral infection, certain medications, or other immune stress - is the prevailing theory. It's not directly inherited, but first-degree relatives of affected patients do have a somewhat higher risk and should be aware of the symptoms. Suspected autoimmune liver disease or have unexplained liver enzyme elevations? These conditions need specialist evaluation for an accurate diagnosis and the right treatment.

© 2026 Dr. Gaurav. All Rights Reserved.